5 recruiting, 1 completed. 3 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 1 | 2 | Recruiting 2 |
| Not applicable | 1 | Completed 1 |
Follow Resectable Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Resectable Head and Neck Squamous Cell Carcinoma trials Research Report on Resectable Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma Sacituzumab Govitecan, Tagitanlimab - Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | West China Hospital | 30 | 2026-05-11 | 2026-05-13 |
| Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer Biospecimen Collection, Chemotherapy, Decitabine - Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 32 | 2026-01-23 | 2026-07-15 |
| Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 28 | 2025-11-18 | 2026-06-26 |
| Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Pembrolizumab, CISPLATIN, Carboplatin - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 28 | 2023-05-20 | 2026-06-23 |
| Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab - Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 45 | 2022-05-12 | 2026-07-24 |
| Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers 42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy - Resectable Head and Neck Squamous Cell Carcinoma | Not applicable | Completed | Medical College of Wisconsin | 18 | 2021-12-01 | 2026-05-01 |
Squamous Cell Carcinoma of Head and Neck (3) · Head and Neck Neoplasms (1)
Carcinoma (3) · Carcinoma, Squamous Cell (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Head and Neck Neoplasms (2)
Radiation (2) · Specimen Handling (2) · Surgical Procedures, Operative (2) · pembrolizumab (2) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Congresses as Topic (1) · Decitabine (1) · Docetaxel (1) · Drug Therapy (1) · Injections (1) · Magnetic Resonance Spectroscopy (1) · Radiotherapy (1) · Taxoids (1)
Dana-Farber Cancer Institute (1) · Mayo Clinic (1) · Medical College of Wisconsin (1) · Ohio State University Comprehensive Cancer Center (1) · University of Michigan Rogel Cancer Center (1) · West China Hospital (1)
United States (5) · China (1)
Adam L. Holtzman, MD (1) · Dukagjin M Blakaj, MD, PhD (1) · Kartik Sehgal, MD (1) · Musaddiq Awan, MD (1) · Paul L Swiecicki (1)